BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PLX-PAD cells: Additional Phase I data

Additional data from a pair of open-label, dose-escalation, U.S. and German Phase I trials in 27 patients showed that intramuscular PLX-PAD cells led to an amputation-free survival (AFS) rate of 85.2%...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >